The semaglutide titration schedule is a structured dose escalation protocol designed to minimize GI side effects while achieving therapeutic plasma concentrations. The standard protocol used in STEP trials escalates from 0.25 mg/week to 2.4 mg/week over 16-20 weeks.
The FDA-approved titration schedule for Wegovy (semaglutide 2.4 mg) follows 4-week intervals: Weeks 1-4: 0.25 mg/week (initiation dose). Weeks 5-8: 0.5 mg/week (first therapeutic dose). Weeks 9-12: 1 mg/week. Weeks 13-16: 1.7 mg/week. Week 17+: 2.4 mg/week (maintenance dose). Each escalation step allows GLP-1 receptors in the GI tract to adapt, significantly reducing nausea and vomiting rates.
For subjects with high GI sensitivity, an extended 8-week titration interval is used: Weeks 1-8: 0.25 mg/week. Weeks 9-16: 0.5 mg/week. Weeks 17-24: 1 mg/week. Weeks 25-32: 1.7 mg/week. Week 33+: 2.4 mg/week. This doubles the titration period but reduces peak nausea rates from ~44% to approximately 18-22%. Total weight loss at 52 weeks is comparable.
If GI side effects are intolerable at a given dose, hold at the current dose for an additional 4 weeks before attempting escalation. Dose reduction (stepping back one level) is used only if side effects persist beyond 8 weeks at a given dose. Most subjects who hold at 0.5 or 1 mg/week for 8 weeks can successfully escalate thereafter.
The 2.4 mg/week maintenance dose is required to sustain maximum weight loss. Some subjects achieve adequate response at 1-1.7 mg/week. STEP 4 data shows that reducing from 2.4 mg to 1 mg/week results in partial weight regain within 20 weeks, confirming the dose-response relationship.
The standard schedule escalates from 0.25 mg/week (weeks 1-4) to 0.5 mg/week (weeks 5-8), 1 mg/week (weeks 9-12), 1.7 mg/week (weeks 13-16), and 2.4 mg/week (week 17+). Each step is 4 weeks apart to allow GI adaptation.
Accelerating the titration significantly increases nausea and vomiting rates. The 4-week interval is specifically designed to allow GLP-1 receptor desensitization in the GI tract. Faster titration is associated with higher discontinuation rates.
If a dose is missed and the next scheduled dose is more than 5 days away, take the missed dose as soon as possible. If the next scheduled dose is within 5 days, skip the missed dose and resume the regular schedule. Do not double-dose.
The first therapeutic dose is 0.5 mg/week, reached at week 5. The maintenance dose of 2.4 mg/week is reached at week 17 with standard titration, or week 33 with slow titration.
Purgo Labs provides pharmaceutical-grade semaglutide with third-party COAs. Use code HEALTH for 15% off.
Buy Semaglutide at Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.